MCRB · Seres Therapeutics, Inc.
$2.71
+0.08 (+3.04%)
At close · Oct 9
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 5, 2026
Substantial doubt about the company's ability to continue as a going concern.
“these conditions raise substantial doubt about the Company's ability to continue as a going concern. ... As a result, management has concluded that substantial doubt exists about the Company's ability to continue as a going concern for 12 months from the date these condensed consolidated financial statements are issued.”View the 10-Q filed Aug 5, 2026
Market Cap
$26.94M
Shares
9.94M
Volume · Oct 9
79.41K
Avg daily vol (3M)
73.55K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.71
Open$2.65
Day$2.58–2.75
52W close$2.63–28.63
Avg vol 30d71K
Short int314K · 3.2% float · 5.2d
Short vol67%
Last earningsNov 5, 2025
DataJan 2020–Oct 2026
Filing10-Q · Aug 5
Up next
filed Aug 5, 2026
call held Nov 5, 2025
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$1.88M
Trailing 12 months
Net income (TTM)
−$22.46M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
-4,462.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-190.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+11.5%
Year over year · more shares
Price change (1Y)
-86.1%
Trailing year
Short interest
3.2%
Latest settlement · 5.2 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 14.8 · calm
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−66%
below
Price vs 50-day avg
−38%
below
RSI (14)
22
oversold
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−46%
trailing
6-month return
−70%
trailing
YTD return
−82%
this year
Relative strength
−80%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $8 — 200d above 50d
Institutional flow
Accumulating
+3% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.16% of float · ▲ +4.3% MoM · 5.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
35 holders — near 3-yr low, contrarian setup
Squeeze score
56
elevated · 0–100
Fundamentals
Free cash flow
$865.0K
Balance sheet
$18.0M
net cash
Quant / Vol
risk profile
Volatility
89%
annualized · 1-yr
Max drawdown
−91%
past year
ATR
11.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−66%
Bearish
Price vs 50-day avg
−38%
Bearish
RSI (14)
22
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $4 › 200d $8 — 200d above 50d
Institutional flow
Accumulating
+3% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.16% of float · ▲ +4.3% MoM · 5.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
35 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $3
Now $3 · 0%
Range high $29
vs 200-day avg -66%
vs 50-day avg -38%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Impairment of long-lived assets | $5.8M | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MCRB
this stock
Seres Therapeutics, Inc.
|
$26.94M | -81.8% | -95.0% | — | 3.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$129.29B | +12.5% | +46.2% | 29.7 | 1.8% |
|
MRNA
Moderna, Inc.
|
$89.83B | +663.0% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.86B | -3.3% | +20.8% | 18.5 | 2.1% |
|
CSLLY
Csl Ltd
|
$61.83B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MCRB | -7.8% | -45.9% | -69.7% | -19.1% | -81.8% |
| SPY | +1.2% | +1.9% | +9.9% | +2.1% | +14.2% |
| vs SPY | -9.0% | -47.8% | -79.6% | -21.2% | -96.0% |